PureTech Health (NASDAQ:PRTC) Shares Up 2% – Still a Buy?

Shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) rose 2% during mid-day trading on Thursday . The stock traded as high as $19.11 and last traded at $19.05. Approximately 1,237 shares changed hands during trading, a decline of 59% from the average daily volume of 2,999 shares. The stock had previously closed at $18.67.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of PureTech Health in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

PureTech Health Trading Up 2.0%

The business’s 50-day simple moving average is $17.44 and its two-hundred day simple moving average is $17.54.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Persistent Asset Partners Ltd bought a new stake in PureTech Health during the 2nd quarter valued at $29,000. Diadema Partners LP purchased a new position in shares of PureTech Health in the second quarter valued at $126,000. Lansdowne Partners UK LLP bought a new stake in shares of PureTech Health during the 3rd quarter valued at $260,973,000. Finally, Pentwater Capital Management LP raised its stake in shares of PureTech Health by 50.0% during the 3rd quarter. Pentwater Capital Management LP now owns 75,000 shares of the company’s stock valued at $1,388,000 after purchasing an additional 25,000 shares during the period. 0.04% of the stock is currently owned by hedge funds and other institutional investors.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.